Hormonal
Insulin-resistant subjects experience a significant reduction in whole-body norepinephrine spillover after weight loss, whereas insulin-sensitive subjects do not, despite similar weight loss amounts.
If you have metabolic syndrome and are insulin resistant, weight loss is particularly effective at calming your nervous system's stress response. If you are already insulin sensitive, weight loss still helps other metabolic markers, but may not lower sympathetic nerve activity as dramatically.
Subgroup analyses (Fig. 4) showed that only those subjects who were insulin resistant at baseline (HOMA, (cid:1)2.5) experienced a significant reduction in norepinephrine spillover despite similar weight loss in insulin-resistant and insulin-sensitive subjects (6.4 (cid:1) 1.1 and 6.6 (cid:1) 1.0 kg, respectively; P (cid:2) 0.88).
Why this rating
Clear subgroup analysis with statistical significance, though sample size for subgroups is smaller.
Source
Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome
Nora E. Straznicky et al. · The Journal of Clinical Endocrinology & Metabolism · 2005
DOI 10.1210/jc.2005-0961
More from this paper
- Dietary weight loss via a hypocaloric DASH-based diet significantly reduces sympathetic nervous system (SNS) activity (norepinephrine spillover and muscle sympathetic nerve activity) and improves cardiac baroreflex sensitivity in subjects with metabolic syndrome.Good
- The reduction in sympathetic activity (norepinephrine spillover) following weight loss is independently associated with the reduction in plasma leptin concentrations, suggesting leptin mediates this effect.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →